FDA Says Retatrutide Is a Drug, Not a Biologic: What It Means

Short answer: on October 2, 2026 the FDA told Eli Lilly that retatrutide is a drug, not a biological product, so “an application for retatrutide would need to be submitted under section 505 of the Federal Food, Drug, and Cosmetic Act.” That is a New Drug Application (NDA), not the Biologics License Application (BLA) Lilly has said it will file in the first quarter of 2027. Lilly is contesting the classification in court, the appeal has not been decided, and Lilly has not said publicly how it will file. The classification does not change who reviews the drug or how long review takes. It mainly affects how long retatrutide is protected from copies after approval and whether pharmacies could ever compound it.

Why a peptide can be a “drug” or a “biologic”

Since March 23, 2020, US law has treated proteins as biological products. The FDA defined a protein in regulation (21 CFR 600.3(h)(6)) as “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.” Anything at or below 40 amino acids is a peptide and stays a drug. On that date, approved drugs that met the new definition, such as insulins and human growth hormone, were moved from drug approvals to biologics licences.

The statute also covers products “analogous” to a protein. Whether retatrutide is “analogous” to a protein is the whole dispute.

Retatrutide has a backbone of 39 amino acids, with a side chain attached at one position (lysine 17) that carries a fatty acid. The fatty acid lets it bind to albumin in the blood, which gives it the long half-life that makes once-weekly dosing possible. Lilly argued the molecule counts as 41 units and is analogous to a protein. The FDA counts it differently.

How the dispute got here

On the protein question the district court was blunt: “the regulation unambiguously requires that proteins contain at least forty-one alpha amino acids,” and retatrutide “contains forty alpha amino acids at most.” On the analogous question it sided with Lilly, saying the FDA’s “‘bright line’ approach flouts the statutory text,” and sent the issue back to the agency to define what makes a product analogous to a protein.

What the FDA decided on October 2

The FDA’s letter, signed by its Principal Regulatory Counsel at the Center for Drug Evaluation and Research, does three things.

1. It sets a two-part test. To be analogous to a protein, a product must have (a) one or more chains of alpha amino acids, linked by peptide bonds, that together total more than 40 alpha amino acids, and (b) a specific, defined sequence. Missing either one disqualifies it.

2. It applies the test to retatrutide. “Retatrutide is composed of a chain of 39 alpha amino acids.” The side chain does not change the count: its linker (ADO) is an amino acid but not an alpha amino acid, and its gamma-glutamate is an alpha amino acid but is not part of a chain. Even counting gamma-glutamate, “the total number of alpha amino acids would only total 40, which is below the required threshold.” The FDA says it “does not agree with the number ‘41’” Lilly drew on its diagram. It accepts that retatrutide has a defined sequence, so it fails only on size.

3. It points to tirzepatide. Lilly’s own tirzepatide (Mounjaro, Zepbound) has the same kind of structure, a 39-amino-acid chain with a fatty-acid side chain, and was approved as a drug under NDAs. The FDA notes that Lilly’s 2023 Mounjaro label described tirzepatide as “a 39-amino-acid … peptide.”

The letter’s conclusion: retatrutide “is neither a ‘protein’ nor an ‘analogous product’ to a ‘protein’ and is therefore not a biological product.”

Where the court case stands

The Seventh Circuit heard argument on September 24, 2026 but has not ruled. It first asked whether it can hear the appeal at all.

• The government argues that “a private party such as Eli Lilly cannot appeal a district court’s order remanding to an agency,” and that Lilly should challenge the new decision in a new lawsuit.
• Lilly argues the court does have jurisdiction, and that on remand the FDA “announced a nearly identical bright-line rule.” It acknowledges that to challenge the October 2 decision itself, “it will have to initiate a new suit.”

Possible outcomes include the appeal being dismissed for lack of jurisdiction, a ruling on the protein question, or a new lawsuit over the October 2 decision. As of October 22, 2026, none of these has happened.

What the classification changes, and what it does not

It does not change who reviews retatrutide or the review clock. The FDA states that its drug center (CDER) “will be responsible for the review of retatrutide, regardless of whether it is classified as a ‘drug’ or a ‘biological product’.” Under the FDA’s user-fee commitments, a new molecular entity NDA and an original BLA have the same review goals: about 10 months after the 60-day filing period for standard review, or 6 months for priority review.

It changes the protection from copies. These are the statutory rules; how they would apply to retatrutide is our analysis.

Patents are separate and often last longer than either exclusivity period, so the practical difference depends on Lilly’s patents, which this article does not assess.

It may matter for compounding, after approval. Licensed biologics “are not eligible for the exemptions for compounded drugs under sections 503A and 503B,” the FDA says. If retatrutide is approved as a drug instead, its active ingredient would become a component of an approved drug, which is one of the conditions under which a licensed pharmacy may compound a drug under section 503A, subject to other limits, including a ban on regularly making copies of a commercially available product. Whether any lawful compounding of retatrutide would follow is uncertain and would depend on rules, shortages and enforcement at the time. Before approval, nothing changes: any retatrutide sold outside a clinical trial is an unapproved drug, and the FDA has already sent warning letters to sellers (see our black-market report).

That is why Lilly is contesting the classification even though it does not affect when patients could get the drug.

Does this delay approval?

Probably not by itself, though nobody can say for certain. The review clock is the same for both application types and the same FDA center reviews it either way. A delay could come only if Lilly had to reformat its application or chose to wait for the courts, and there is no public sign of either. Lilly’s last public statements, on August 5 and September 29, 2026, both before the FDA’s letter, said it plans to submit a BLA in the first quarter of 2027. Its next scheduled update is its third-quarter results on October 29, 2026. See our refreshed approval timeline.

Frequently asked questions

Is retatrutide a biologic?

Not according to the FDA. On October 2, 2026 the agency decided retatrutide is a drug because its amino acid chain is 39 units long, below the more-than-40 threshold for a protein or a product analogous to one. Lilly disputes this and the matter is before the courts.

Will Lilly now file an NDA instead of a BLA?

Lilly has not said. Its latest public statements, made before the FDA’s letter, refer to a BLA in the first quarter of 2027.

Does the ruling make retatrutide available sooner, or allow compounding now?

No. Retatrutide is still unapproved, so it cannot lawfully be sold or compounded for patients. The classification matters only after approval. See Is Retatrutide Approved?

How many amino acids does retatrutide have?

Its main chain has 39 alpha amino acids, with a side chain carrying a fatty acid. Lilly counts it as 41 units; the FDA and the district court counted 40 at most.

This article explains a regulatory and legal dispute for general readers and is not legal advice. Court filings are linked in the references.